Surrogate Marker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The new Lockdown Craze sweeping the globe. Welcome to our viewers on pbs in america and around the globe. Major trials of a new vaccine have shown its effective against some new variants of covid 19, helping to reduce fears that they might prove resistant. Novavax is an american jab but its being produced in the uk. Its also easier to roll out than some previous vaccines since it doesnt need to be kept at ultra low temperatures. The news came amid a deepening row between another vaccine maker, astrazeneca, and the European Union over shortages. Our medical editor fergus walsh reports. Once aga...

/PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, announced today that the Company and its collaborators present clinical data...

Pfizer to submit their two dose data to them for authorization, they said in part this afternoon that the fda felt it was their responsibility as a public health agency to act with urgency and have all available options including they provide us with initial data on two doses from the on going study, their goal was to understand if two dose was provide sufficient protection. remember, we had press release information already in december from pfizer that said, you know, there two dose regimen in this age-group did not trigger a comparable immune response as what was seen in 16 to 25-year-olds. ...

The studies, actually, the pivotal studies and the primary end point is the slowing of cognitive decline and there we had two findings. one trial was negative and one trial showed some benefit and what the fda is saying is that they're using this finding that it can reduce these plaques into a surrogate marker, but it's not actually what the studies showed. there in lies the controversy, jeff. >> the fda approved it anyway because their determination is the benefits of the treatment outweigh any potential risk? >> well, certainly, the benefit risk equation is always on the table for the fda, b...